Organigram Global Inc.
OGI Healthcare Drug Manufacturers Specialty & Generic
Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024. In the quarter to June 2026, revenue grew 49.3%, EPS grew 1,966.7% and free cash flow fell 192.3%, each against the same quarter a year earlier.
Follow OGI
Organigram Global Inc. (OGI) EV/Sales
As of 16 October 2026, Organigram Global Inc. (OGI) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.0× (May 2019) to 21.4× (June 2019); the current reading is higher than 8% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | 69.28% |
| FY2024 | 0.6× | (2.86%) |
| FY2023 | 0.7× | (83.49%) |
| FY2023 | 4.0× | 79.05% |
| FY2022 | 2.2× | (74.43%) |
| FY2021 | 8.6× | 125.14% |
| FY2020 | 3.8× | (61.68%) |
| FY2019 | 10.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.6× | (6.01%) |
| Mar 2026 | 0.7× | (24.02%) |
| Dec 2025 | 0.9× | (15.60%) |
| Sep 2025 | 1.1× | 44.82% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLVR Clever Leaves Holdings Inc. compare | −0.3× |
| BGM BGM Group Ltd. compare | −0.1× |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| ORGO Organogenesis compare | 0.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| OGI Organigram Global Inc. | 0.6× |
| PROCF Sofgen Pharma S.A compare | 0.7× |
| DERM Journey Medical Corporation compare | 2.0× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)